Human Performance Laboratory, Ball State University, Muncie, IN 47306, USA.
Am J Physiol Endocrinol Metab. 2010 Feb;298(2):E354-61. doi: 10.1152/ajpendo.00423.2009. Epub 2009 Nov 24.
Nonselective blockade of the cyclooxygenase (COX) enzymes in skeletal muscle eliminates the normal increase in muscle protein synthesis following resistance exercise. The current study tested the hypothesis that this COX-mediated increase in postexercise muscle protein synthesis is regulated specifically by the COX-2 isoform. Sixteen males (23 +/- 1 yr) were randomly assigned to one of two groups that received three doses of either a selective COX-2 inhibitor (celecoxib; 200 mg/dose, 600 mg total) or a placebo in double-blind fashion during the 24 h following a single bout of knee extensor resistance exercise. At rest and 24 h postexercise, skeletal muscle protein fractional synthesis rate (FSR) was measured using a primed constant infusion of [(2)H(5)]phenylalanine coupled with muscle biopsies of the vastus lateralis, and measurements were made of mRNA and protein expression of COX-1 and COX-2. Mixed muscle protein FSR in response to exercise (P < 0.05) was not suppressed by the COX-2 inhibitor (0.056 +/- 0.004 to 0.108 +/- 0.014%/h) compared with placebo (0.074 +/- 0.004 to 0.091 +/- 0.005%/h), nor was there any difference (P > 0.05) between the placebo and COX-2 inhibitor postexercise when controlling for resting FSR. The COX-2 inhibitor did not influence COX-1 mRNA, COX-1 protein, or COX-2 protein levels, whereas it did increase (P < 0.05) COX-2 mRNA (3.0 +/- 0.9-fold) compared with placebo (1.3 +/- 0.3-fold). It appears that the elimination of the postexercise muscle protein synthesis response by nonselective COX inhibitors is not solely due to COX-2 isoform blockade. Furthermore, the current data suggest that the COX-1 enzyme is likely the main isoform responsible for the COX-mediated increase in muscle protein synthesis following resistance exercise in humans.
非选择性环氧化酶 (COX) 抑制剂会消除阻力训练后肌肉蛋白合成的正常增加。本研究旨在验证 COX 介导致力训练后肌肉蛋白合成增加的假设,具体是由 COX-2 同工酶调控的。16 名男性(23±1 岁)被随机分为两组,在单次股四头肌伸肌抗阻运动后 24 小时内,分别接受三种剂量选择性 COX-2 抑制剂(塞来昔布;200mg/剂,共 600mg)或安慰剂的双盲治疗。在休息和运动后 24 小时,使用 [(2)H(5)]苯丙氨酸的脉冲恒速输注和股外侧肌活检来测量骨骼肌蛋白合成率(FSR),并测量 COX-1 和 COX-2 的 mRNA 和蛋白表达。与安慰剂(0.074±0.004 至 0.091±0.005%/h)相比,COX-2 抑制剂(0.056±0.004 至 0.108±0.014%/h)并没有抑制混合肌肉蛋白对运动的反应(P<0.05),并且在控制休息时的 FSR 后,安慰剂和 COX-2 抑制剂之间也没有差异(P>0.05)。COX-2 抑制剂不影响 COX-1 mRNA、COX-1 蛋白或 COX-2 蛋白水平,但与安慰剂相比,它确实增加了 COX-2 mRNA(3.0±0.9 倍)(1.3±0.3 倍)。看来,非选择性 COX 抑制剂消除运动后肌肉蛋白合成反应不仅仅是由于 COX-2 同工酶的阻断。此外,目前的数据表明,COX-1 酶可能是人类抗阻运动后 COX 介导致肌肉蛋白合成增加的主要同工酶。